Completed PHASE4 INTERVENTIONAL 2-arm NCT00370240

Chlorhydrate of Ropivacaine and Breast Cancer Surgery

Efficacy of Infiltration of Chlorhydrate of Ropivacaine in the Prevention of Chronic Breast Pain After Surgery for Breast Cancer.

Sponsor: AstraZeneca

Conditions Breast Neoplasms Pain,Postoperative

Interventions Chlorhydrate de Ropivacaine placebo

Updated 6 times since 2017 Last updated: Sep 17, 2025 Started: Sep 30, 2006 Primary completion: Jul 31, 2007 Completion: Nov 30, 2008

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE4 clinical study on Breast Neoplasms and Pain,Postoperative, this trial is completed. The trial is conducted by AstraZeneca and has accumulated 6 data snapshots since 2006. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

6 versions recorded

Oct 2025 — Present [monthly]

Completed PHASE4
Sep 2024 — Oct 2025 [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4
Jun 2018 — Jan 2021 [monthly]

Completed PHASE4

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE4

First recorded

Sep 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

AstraZeneca
Gustave Roussy, Cancer Campus, Grand Paris
Institut Curie

Data source: Institut Curie

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Saint-Cloud, France